Last reviewed · How we verify
Prevacid
At a glance
| Generic name | Prevacid |
|---|---|
| Also known as | lansoprazole, Lansoprazole (generic name), Lansoprazole |
| Sponsor | Vanderbilt University Medical Center |
| Target | ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
- Duodenal Ulcer due to H. Pylori
- Duodenal ulcer disease
- Erosive esophagitis
- Gastric Hypersecretory Conditions
- Gastric ulcer
- Gastroesophageal reflux disease
- Maintenance of Healing Duodenal Ulcer
- NSAID-Induced Gastric Ulcer
- Peptic ulcer
- Zollinger-Ellison syndrome
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Constipation
Serious adverse events
- Myocardial infarction
- Cerebrovascular accident/cerebral infarction
- Gastrointestinal hemorrhage
- Esophageal ulcer
- Shock (circulatory failure)
- Syncope
- Hematemesis
- Melena
- Esophageal stenosis
- Renal impairment
Key clinical trials
- A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (PHASE2)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevacid CI brief — competitive landscape report
- Prevacid updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI